Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

Start Date31 Jul 2026

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nimes

NCT07610486

/ RecruitingPhase 1/2IIT

An Open-label, Pharmacokinetic and Safety Trial Optimizing PreTerm Infant Ampicillin Dosing

The goal of this clinical trial is to learn if preterm infants who are prescribed antibiotics shortly after birth can safely receive a shorter course of antibiotics (24 to 36 hours instead of 48 hours). The main questions it aims to answer are:
* Does short-course ampicillin provide high enough levels of ampicillin at 48 hours?
* Is short-course ampicillin safe for preterm infants to receive?
Preterm infants who are being prescribed ampicillin by their doctor and enroll in the study will stop ampicillin after a shorter than typical course, and researchers will collect blood samples to measure their ampicillin levels and follow them clinically to see how they do after receiving short-course ampicillin.
Participants will:
* stop ampicillin earlier than 48 hours (between 24 to 36 hours, depending on how premature they are and the dosing of ampicillin their doctor has prescribed)
* have one or more blood samples collected, including one around 48 hours from when they started ampicillin
* have their data collected until 30 days after they receive short-course ampicillin, or until hospital discharge, whichever is sooner

Start Date28 Jul 2026

Sponsor / Collaborator

Duke University

100 Clinical Results associated with Ampicillin

100 Translational Medicine associated with Ampicillin

100 Patents (Medical) associated with Ampicillin

46,813

Literatures (Medical) associated with Ampicillin

01 Feb 2027·TALANTA

Towards green monitoring of antibiotics: a direct biochar-based electrochemical sensor for ampicillin detection in biomedical and environmental matrices

Article

Author: Tertis, Mihaela ; Oprean, Radu ; Macovei, Diana-Gabriela ; Leoştean, Cristian ; Kacsó, Irina ; Cristea, Cecilia ; Cherecheş, Răzvan M ; Suciu, Maria ; Tripon, Septimiu ; Balla, Ancuța

Antimicrobial resistance (AMR) represents a global health burden, requiring effective monitoring of antibiotic residues across the clinical-environmental chain. However, reference methods remain laboratory-based and solvent-intensive. To address this need in an ecologically responsible manner, this study exploits KOH-activated biochar derived from spent coffee grounds (BCK-KOH) as a screen-printed carbon electrode modifier for the direct detection of ampicillin (AMP); the corresponding non-activated material is denoted BCK. Characterization by N₂ adsorption, FTIR, XPS and SEM-EDS revealed a 168-fold increase in BET surface area and substantial enrichment in surface carboxyl groups following activation. Modification with a PEI/BCK-KOH composite produced a ∼370 mV cathodic shift of the AMP oxidation signal compared with the unmodified electrode. Under optimized differential pulse voltammetry (DPV), the platform exhibited a linear range of 0.01-5 μM, an LOD of 3.3 nM, an LOQ of 10 nM and a sensitivity of 64.7 μA μM^-1 (R² = 0.997). The sensor showed acceptable interference tolerance toward the tested antibiotics and common endogenous compounds. Validation in artificial and ICU-patient serum, milk and water samples yielded recoveries of 88.5-111.4% with RSDs below 5.6% (n = 3), without pre-treatment. Because the LOQ closely matches the EU maximum residue limit (MRL) for AMP in milk, the platform enabled quantitative determination at approximately the MRL, 1.5×MRL and 2×MRL, with recoveries of 90.9%, 101.9% and 100.9%, respectively, while also supporting qualitative MRL screening in diluted samples complementary to confirmatory LC-MS/MS. AGREE (0.75) and BAGI (67.5) scores confirmed a substantially greener analytical platform than LC-MS/MS (AGREE 0.43) with practical applicability.

01 Feb 2027·COMPUTATIONAL BIOLOGY AND CHEMISTRY

In silico screening of phytochemical inhibitors against Agrobacterium proteins using ADMET prediction, molecular docking, molecular dynamics simulation, and in vitro antimicrobial evaluation

Article

Author: Attar, Shahid ; Phatake, Yogesh ; Marathe, Rajendra

PURPOSE/OBJECTIVE:

Multidrug resistance (MDR) in Agrobacterium tumefaciens poses significant challenges to agriculture and health. This study aimed to identify safe, plant-derived phytochemicals that inhibit essential Agrobacterium proteins, using an integrated in silico and in vitro approach.

METHODS:

A library of 1816 phytocompounds was screened for drug-likeness and ADMET properties. Key bacterial target proteins including MotA, Enolase, Malate dehydrogenase, Penicillin V acylase, ABC transporter, D-β-lactamase, TetR, and TraR were selected for molecular docking. Both phytochemicals and reference antibiotics (tetracycline, ampicillin, carbenicillin, chloramphenicol, kanamycin) were docked and compared. For top-binding complexes underwent molecular dynamics (MD) simulations and MM/GBSA binding free energy analysis to assess the stability and energetics of ligand-protein interactions. Experimental validation was performed using MIC, MBC, and resazurin based-cell viability assays against MDR Agrobacterium strain.

RESULTS:

Piperine, curcumin, and quercetin demonstrated high drug-likeness, favorable ADMET and toxicity, and strong binding affinities (up to -9.9 kcal/mol) with target proteins. MD simulations and MM/GBSA analysis confirmed the stable binding and favorable energetics of the piperine-TraR complex. In vitro, these phytochemicals inhibited growth of both sensitive and resistant strains, with piperine exhibiting the lowest MIC among the tested phytocompounds.

CONCLUSIONS:

This integrative in silico and experimental strategy identified safe, multi-target phytochemicals, especially piperine as promising alternatives to antibiotics for combating MDR Agrobacterium. The use of MD simulation and in vitro experiments provided robust support of binding stability and biological activity, supporting further optimization and in vivo studies.

01 Jan 2027·VETERINARY RESEARCH COMMUNICATIONS

Antimicrobial susceptibility of E. coli isolated from dairy cow milk in Egypt and antibacterial activity of selected nanomaterials against MDR strains

Article

Author: Auda, H M ; Bakry, N M ; Youssef, Fady Sayed ; Abdel Massieh, E S ; Bahr, A D

Escherichia coli (E. coli) is a significant livestock and foodborne pathogen. This study was designed to isolate E. coli from raw cow milk, evaluate its antimicrobial susceptibility, and investigate the antimicrobial activity of silver nanoparticles (nAg), zinc oxide nanoparticles (nZnO), and Moringa nano-emulsion (MNE) against multidrug resistant (MDR) strains. A total of 146 individual milk samples were obtained from dairy cows in Egypt. E. coli were isolated by standard culture methods and pathotyped using molecular techniques. The antibiotic resistance of the isolates was determined, and the antimicrobial activity of the selected nanomaterials was evaluated using the broth microdilution method on the identified MDR strains. E. coli was detected in 54.8% (80/146) of the samples; 42 out of 80 (52.5%) were virulent strains, including STEC (15/42; 35.7%), ETEC (12/42; 28.57%), EPEC (12/42; 28.57%), and AE-STEC (3/42; 7.1%). The isolated strains showed the highest resistance rate to sulfa-trimethoprim (52.5%), tetracycline (45%), and ampicillin (42.5%); and the lowest against marbofloxacin (8.75%) and ceftiofur (27.5%). Overall, 42.5% of the E. coli strains exhibited MDR, including virulent and non-virulent strains at 45.2% (19/42) and 39.47% (15/38), respectively. The minimum inhibitory concentration (MIC) values against MDR E. coli isolates were lowest for nAg (1.56-12.5 µg/mL), followed by nZnO (12.5-50 µg/mL). In contrast, Moringa nano-emulsion (MNE) requires much higher concentrations (125-250 µg/mL) for growth inhibition. Raw cow milk is a potential source of pathogenic and MDR E. coli, emphasizing continuous surveillance and prudent antimicrobial use. Although selected nanomaterials showed consistent in vitro efficacy, further studies are required before considering practical veterinary applications.

News (Medical) associated with Ampicillin

15 Jul 2026

·www.einpresswire.com

A Complete Guide to Pharmaceutical Ingredients: Serum Pharma’s APIs, Plant Extracts & Nutraceutical Solutions

NANCHANG, JIANGXI, CHINA, July 15, 2026 / EINPresswire.com / -- Jiangxi Serum Pharma Industries Supports Global Healthcare with High-Quality Pharmaceutical Ingredients and Nutritional Solutions The pharmaceutical and healthcare industries are continuously evolving, with increasing demand for reliable active pharmaceutical ingredients (APIs), biological products, natural extracts, and nutritional compounds. As pharmaceutical manufacturers and healthcare companies worldwide seek stable supply chains and trusted partners, professional ingredient suppliers play an increasingly important role in ensuring product quality, safety, and innovation. Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly ten years, the company has been dedicated to exporting a wide range of healthcare-related products, including biological products, vaccines, Western medicines, pharmaceutical raw materials, intermediates, medical consumables, food additives, and plant extracts. Through years of industry experience and continuous improvement, Serum Pharma has developed strong capabilities in global pharmaceutical supply and customer service. Understanding the Role of Pharmaceutical Ingredients in Modern Healthcare Pharmaceutical ingredients are the foundation of medicine manufacturing, directly influencing the effectiveness, stability, and quality of finished healthcare products. From antibiotic APIs used in pharmaceutical production to natural plant extracts and functional nutritional ingredients, each component requires strict quality control and professional supply management. Today’s global pharmaceutical market requires suppliers that can provide: Reliable raw material sourcing Stable production and supply capabilities Strict quality assurance systems International export experience Competitive pricing and professional support With extensive cooperation networks and industry knowledge, Jiangxi Serum Pharma provides customers with comprehensive solutions for pharmaceutical, healthcare, and nutrition-related applications. Advanced Antibiotic APIs Supporting Pharmaceutical Manufacturing Antibiotic ingredients remain one of the most important categories in global pharmaceutical production. High-quality antibiotic APIs and pharmaceutical intermediates are essential for producing effective medicines used in infection treatment and healthcare applications. Serum Pharma supplies a variety of antibiotic-related pharmaceutical products, including Cefuroxime Sodium Injection, Cefotaxime Sodium Injection, Ampicillin Capsules, Cloxacilin Sodium Injection, Benzylpenicillin Sodium Injection, Amoxicillin Sodium Injection, Oxacilin Sodium Injection, and Amoxicillin Capsules. In addition, the company provides pharmaceutical-grade active ingredients such as Ampicillin Trihydrate (API), Dicloxacillin Sodium (API), and Ceftriaxone Sodium (API), supporting pharmaceutical manufacturers that require dependable raw material sources for medicine development and production. By cooperating with qualified domestic pharmaceutical manufacturers, Serum Pharma establishes stable supply channels and carefully manages product quality from sourcing to shipment. This approach helps customers maintain production consistency while meeting the requirements of different international markets. Plant Extracts Supporting Natural Health Product Development In addition to pharmaceutical ingredients, the demand for botanical extracts and natural health ingredients has grown rapidly worldwide. Consumers are increasingly interested in functional foods, dietary supplements, and wellness products based on natural ingredients. Jiangxi Serum Pharma provides various plant-based ingredients, including Green Tea Extract, Black Tea Extract, L-Theanine from Green Tea, Bilberry Extract, Grape Seed Extract OPC, Ganoderma lucidum Extract, Goji berry Extract, Chrysanthemum Powder, and Cordyceps sinensis Extract. These natural ingredients are widely used in applications such as: Nutritional supplements Functional beverages Health food products Botanical formulations Wellness and lifestyle products Through professional sourcing and quality management, Serum Pharma helps customers develop innovative health products that meet the growing global demand for natural and functional solutions. Expanding Nutraceutical Ingredient Solutions for Global Markets Alongside traditional pharmaceutical products and plant extracts, the nutraceutical industry has become an important area of growth. Modern consumers are increasingly focused on preventive healthcare, nutrition improvement, and long-term wellness management. To support this trend, Serum Pharma supplies a range of nutritional ingredients, including Peach Fruit Powder, Pea Protein Peptides, Fava Bean Protein Peptides, Mung Bean Protein Peptides, Medium Chain Triglyceride (MCT), Flaxseed Oil Powder, Akkermansia muciniphila, Coenzyme Q10 Ubidecarenone, and β-Nicotinamide Mononucleotide (NMN). These ingredients are commonly applied in areas such as: Sports nutrition Functional foods Anti-aging products Metabolic health solutions Dietary supplements By integrating pharmaceutical expertise with nutritional ingredient supply capabilities, Serum Pharma provides customers with diversified solutions for the expanding global health industry. Global Market Expansion and International Pharmaceutical Experience With years of dedication to international trade, Jiangxi Serum Pharma Industries has successfully exported products to more than 30 countries across Asia, Africa, South America, the Middle East, and Europe. The company’s global markets include countries such as: Philippines Bangladesh Laos Cambodia Kyrgyzstan Cameroon Guinea Nigeria Liberia Mali Yemen Turkey Chile Australia Through continuous efforts, Serum Pharma has developed into a trusted supplier in the pharmaceutical industry. Its products have gained recognition in regions including Southeast Asia, Africa, and South America due to reliable quality and competitive pricing. In markets such as the Philippines, Pakistan, Egypt, Nigeria, Guinea, Ethiopia, and Tanzania, Serum Pharma has established long-term partnerships with distributors and terminal users, building a strong reputation for professional service and dependable product supply. Strict Quality Assurance Ensuring Reliable Pharmaceutical Supply Quality is a core priority at Jiangxi Serum Pharma Industries. The company has established a complete quality assurance system based on China’s pharmaceutical export supervision requirements and the standards of overseas markets. From raw material procurement to final shipment, every process is carefully managed by the company’s quality assurance department. The quality control process includes: Selecting qualified suppliers Reviewing supplier capabilities Inspecting products before delivery Maintaining product documentation Ensuring quality traceability Serum Pharma’s products have obtained multiple certifications, including the Chinese GMP Certificate and ISO9001 Quality Certification, demonstrating the company’s commitment to reliable pharmaceutical production and international quality standards. Why Choose Jiangxi Serum Pharma as Your Pharmaceutical Ingredient Partner? Jiangxi Serum Pharma has established close cooperative relationships with domestic manufacturers of biological products, vaccines, raw materials, excipients, and plant extracts. Through resource sharing and complementary advantages, the company provides customers with stable supply capability and professional pharmaceutical solutions. Key advantages include: Professional Industry Experience Nearly ten years of experience in pharmaceutical and nutritional product exports allows Serum Pharma to understand global market requirements and customer expectations. Comprehensive Product Portfolio From antibiotic APIs and pharmaceutical products to plant extracts and nutraceutical ingredients, the company provides diversified solutions for different industries. Reliable Quality Control Strict inspection procedures ensure product reliability, consistency, and traceability throughout the supply chain. Competitive Pricing and Service By optimizing supplier networks and maintaining efficient operations, Serum Pharma provides high-quality products with competitive market advantages. Building the Future of Global Pharmaceutical and Nutritional Supply As healthcare industries continue to develop, the demand for reliable pharmaceutical ingredients, advanced APIs, natural extracts, and nutritional solutions will continue increasing. Suppliers with strong quality systems, global experience, and comprehensive product capabilities will play a vital role in supporting future healthcare innovation. With professional expertise, extensive product resources, strict quality management, and a commitment to Excellence, Professionalism, and Integrity, Jiangxi Serum Pharma Industries Co., Ltd. continues to provide trusted pharmaceutical and nutritional solutions to customers worldwide. The company remains dedicated to expanding its global presence and becoming a long-term partner for pharmaceutical manufacturers, healthcare companies, and distributors seeking reliable ingredient solutions. For more information about Jiangxi Serum Pharma Industries Co., Ltd. and its pharmaceutical ingredient solutions, please visit: https://www.jxserum.com/ JIANGXI SERUM PHARMA INDUSTRIES CO., LTD. JIANGXI SERUM PHARMA INDUSTRIES CO., LTD. + +86-190-6796 3032 miguel.wu@jxserum.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

24 Jun 2026

·www.scripps.edu

Back in action: Researchers make drug-resistant bacteria vulnerable again

New findings from Scripps Research show that disabling a single bacterial protein can restore vancomycin’s power against resistant bacteria–and point to a new strategy for overcoming antibiotic resistance. June 24, 2026 LA JOLLA, CA—Antibiotic resistance is one of the most urgent threats to global health, linked to an estimated 4.7 million deaths worldwide in 2019 alone. As more bacteria evolve to evade even last-resort drugs, the supply of effective treatments is shrinking. Now, scientists at Scripps Research have discovered a way to restore the effect of one of those critical antibiotics by disabling a key bacterial enzyme. The study, published in Nature Communications on June 16, 2026, focused on vancomycin-resistant Enterococcus faecium, or VREfm, a hospital-acquired infection that is becoming increasingly common. VREfm can resist multiple antibiotics held in reserve for the toughest infections, including its namesake, vancomycin, a potent drug often used to treat life-threatening infections. The researchers wanted to know whether disabling a specific bacterial enzyme called secreted antigen A (SagA) could make VREfm vulnerable to vancomycin again, rendering it treatable without needing a new antibiotic. SagA is found across a wide range of VRE strains, making it an attractive target for therapies designed to work broadly against resistant infections. When the researchers genetically deleted the enzyme from VREfm, the bacteria became markedly more susceptible to vancomycin. “The SagA enzyme remodels the cell wall so that bacteria divide properly,” says senior author Howard Hang, a professor at Scripps Research. “If you disrupt that, the bacteria don’t divide as well, and it makes the bacteria more sensitive to vancomycin.” There was already evidence that genetic deletion of the enzyme makes the bacteria more vulnerable to antibiotics, says Hang. “But the fact that it sensitizes the cells to vancomycin, when the bacteria are already resistant to it, was a surprise.” Deleting SagA had little impact on the bacteria's resistance to other antibiotics such as ampicillin, daptomycin and ceftriaxone. This suggested that the deletion wasn’t just making the bacteria frailer overall, but was specifically exposing the site where vancomycin binds. The strategy also worked in a mouse model of sepsis. The researchers also screened a large chemical library and identified a class of compounds called β-chloroalkenyl sulfonyl fluorides that chemically disable SagA. Their lead compound, called pghi-4, reduced the amount of vancomycin needed to kill VREfm by up to 8-fold when the two were combined. The effect held up across multiple clinical isolates and reduced the bacterial burden in infected mice. SagA belongs to a family of cell-wall-remodeling enzymes called NlpC/P60 peptidoglycan hydrolases that no drug had ever successfully targeted before. “To demonstrate you can pharmacologically target this enzyme family is a big step forward,” says Hang. The approach is part of a promising category of treatments known as antibiotic adjuvants: compounds that aren’t antibiotics themselves but help existing antibiotics work better against resistant bacteria. Proven adjuvants already exist for a narrow range of drugs, but this is the first such helper developed for vancomycin. The study data suggest that pghi-4 and related compounds may target other peptidoglycan-remodeling enzymes beyond SagA. That raises the possibility that bacteria carrying extra copies of SagA-like enzymes could be more vulnerable to this approach, which is significant because VREfm strains tend to carry more of these enzymes. “This is a promising new weapon in the ongoing arms race against antibiotic resistance,” says Hang. The broader lesson, he adds, is that targeting basic aspects of bacterial physiology can overcome antibiotic resistance. The researchers are already working on more potent second-generation derivatives that couple the existing compound with vancomycin. They believe the same strategy could eventually be extended to other combinations of resistant bacteria and antibiotics, including pathogens such as tuberculosis and drug-resistant Staphylococcus aureus. In addition to Hang, authors of the study “Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant Enterococcus faecium” include Kyong T. Fam, Pavan Kumar Chodisetti, Adrianna M. Turner, Seiya Kitamura, Benjamin Silva, Yijun Xiong, Althea Hansel-Harris, Matthew Holcomb, Simeon Babarinde, Ian A. Wilson, Stefano Forli, Benjamin F. Cravatt, Donghyun Park, and Dennis W. Wolan of Scripps Research; Zifei Wang, Joshua A. Homer, and John E. Moses of Cold Spring Harbor Laboratory; Christopher J. Smedley of La Trobe University; and Daria Van Tyne of the University of Pittsburgh School of Medicine. This work was supported by the National Institutes of Health (grant R21AT012958) and Scripps Research start-up funds, with additional support from the Cold Spring Harbor Laboratory NCI Cancer Center Support Grant (5P30CA045508), the Australian Research Council (FT170100156), and the F.M. Kirby Foundation For more information, contact press@scripps.edu See More News

23 Jun 2026

·www.sciencedaily.com

One of the world’s most popular weedkillers may be fueling deadly superbugs

Researchers found that highly drug-resistant bacteria from hospitals are also resistant to glyphosate, a commonly used weedkiller. The discovery suggests that agricultural herbicides may be helping antibiotic-resistant microbes survive and spread far beyond healthcare settings.Antimicrobial resistance (AMR) contributes to an estimated 1.1 million to 1.4 million deaths worldwide each year. While this growing threat is typically linked to the overuse and misuse of antibiotics, new research suggests another factor may also be playing a role: certain weedkillers. Scientists have found evidence that glyphosate, one of the world's most widely used herbicides, may help select for bacteria that are resistant to multiple antibiotics. "Here we show that the most common species of multidrug-resistant bacteria from hospitals are not only resistant to multiple antibiotic classes, but also to high concentrations of the weedkiller glyphosate," said Dr. Daniela Centrón, a researcher at the Institute of Medical Microbiology and Parasitology in Buenos Aires and the senior author of the study published in Frontiers in Microbiology. "These results suggest that weedkillers -- which, unlike antibiotics, are widely applied in agricultural environments -- may have the unintended side-effect of selecting for AMR among bacterial communities within the soil." Testing Bacteria From Nature, Farms, and Hospitals To investigate the connection, Centrón and her colleagues analyzed 68 bacterial strains collected in 2018 and 2020 from sediment in a protected nature reserve in the Paraná delta, a wetland region north of Buenos Aires. Although herbicides have never been applied inside the reserve, glyphosate is commonly used in nearby agricultural areas. The researchers examined how resistant each strain was to 16 commonly used antibiotics, including ampicillin combined with sulbactam, meropenem, tetracycline, and vancomycin. They also tested resistance to pure glyphosate and glyphosate-based herbicides, which are among the most widely used weedkillers worldwide. The findings were then compared with 19 bacterial strains obtained from local hospitals, including multidrug-resistant species. An additional 15 strains came from feedlots and agricultural soils affected by herbicide use. Hospital Superbugs Also Resist Glyphosate The hospital strains showed widespread antimicrobial resistance. Individual strains were resistant to between one and 16 of the antibiotics tested. Particularly concerning was the finding that 74% were resistant to carbapenems, a class of broad-spectrum antibiotics often reserved as a last line of defense against serious infections. All of the hospital-derived strains were also highly resistant to glyphosate and glyphosate-based herbicides. "This means that if these bacteria enter the environment through untreated wastewater from hospitals, they could go on to thrive in agricultural areas where glyphosate is used," said first author Dr. Camila Knecht from Dr. Centrón's research group. The 68 strains collected from the Paraná delta represented 15 different genera, including Acinetobacter, Pseudomonas, Exiguobacterium, and Chryseobacterium. Every one of them displayed at least some resistance to glyphosate and glyphosate-based herbicides, despite the fact that these chemicals had never been applied within the reserve itself. Among the environmental strains, Enterobacter species tolerated the highest glyphosate concentrations, surviving levels of up to 80 milligrams per milliliter. In contrast, Bacillus species, which are commonly found in soil, were especially sensitive. Their growth was inhibited at concentrations as low as 2.5 milligrams per milliliter. High glyphosate resistance was also observed in strains isolated from hospital infections that showed extreme drug resistance. Resistant Bacteria Share Similar Genetic Backgrounds The researchers then constructed a genetic "family tree" using all 102 bacterial strains included in the study. They found that bacteria with the greatest glyphosate resistance were often closely related, regardless of whether they originated from hospitals, farms, or the Paraná delta. For example, the same bacterial genera showed glyphosate resistance across all three environments. "In the environment, the use of glyphosate leads to the evolution of resistant bacteria in impacted soils, whereas the use of antibiotics favors their evolution in hospitals. Bacteria carrying antibiotic resistance genes can spread and breed between those two niches in both directions and in multiple ways, with the water cycle playing a key role in transmission," concluded coauthor Dr. Jochen A Müller, a group leader at Karlsruhe Institute of Technology. Concerns About Glyphosate and Public Health Glyphosate has long been the subject of scientific and regulatory debate. Research has shown that it can harm arthropods (in particular bees), and the International Agency for Research on Cancer classifies it as a probable human carcinogen. Several European countries have already restricted some uses of the herbicide. France, Belgium, and the Netherlands have banned glyphosate for household applications, while Germany currently prohibits its use in public spaces. Based on the findings, the researchers argue that pesticide regulations should take antibiotic resistance into account before products reach the market. "Policies for the use of any pesticide, as well as its metabolites, should stipulate the requirement for co-selection testing with antibiotics before marketing. Labels should include a warming that genes for antibiotic resistance can spread from glyphosate-contaminated soils to hospitals through untreated water," counseled Centrón.

Clinical Result

100 Deals associated with Ampicillin

External Link

KEGG	Wiki	ATC	Drug Bank
D02119	Ampicillin	J01CA01 S01AA19	DB00415

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gram-Negative Bacterial Infections	Australia	Demogen Australia Pty Ltd	26 Oct 2026
Gram-Positive Bacterial Infections	Australia	Demogen Australia Pty Ltd	26 Oct 2026
Bacterial Infections	Japan	Meiji Seika Pharma Co., Ltd.	27 Aug 1965

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05156437 (OPTIMAL, CTgov)	Phase 4	Endocarditis	5	Cefalexin+Levofloxacin+Amoxycillin+Oxacillin+Ceftriaxone+Dicloxacillin+Rifampicin+Ampicillin+Linezolid+Daptomycin+Vancomycin (Group I (Experimental))	kxekcepwig(ionbwwyfps) = zbximyutds rqyiegoeqj (lachoytfay, myebasqldl - zipgkyypjk) View more	-	05 May 2026
				Oxacillin+Ceftriaxone+Ampicillin+Daptomycin+Vancomycin (Group II (Control Group))	kxekcepwig(ionbwwyfps) = fzwkpxakrv rqyiegoeqj (lachoytfay, dvuobksbcq - pqcywldwpy) View more
NCT03060473 (TREAT, CTgov)	Phase 3	Preterm Premature Rupture of the Membranes	21	Amoxicillin+Azithromycin+Ampicillin (Azithromycin)	ooiihxqjus(hlkzewsyea) = issqeqmzph jjeujuflau (qzbfvwopii, hpzmjidkym - yfwyfksdcw) View more	-	25 Jun 2024
				Erythromycin+Amoxicillin+Ampicillin (Erythromycin)	ooiihxqjus(hlkzewsyea) = jgodfeargw jjeujuflau (qzbfvwopii, fsexyvbrao - xewfphmbvb) View more
NCT02579161 (CTgov)	Phase 3	Kidney Calculi	98	Fluoroquinolones+cephalosporins+Gentamicin+Ampicillin+Clindamycin (Antibiotics for a 24 Hour Period)	xwgxxxschl = fdgqyrvlhl tkcdfkjych (hvwnmpszrv, udzonvqapj - ahubjhawko) View more	-	14 Mar 2023
				Fluoroquinolones+cephalosporins+Gentamicin+Ampicillin+Clindamycin (Continued Antibiotics)	xwgxxxschl = bhqblikbix tkcdfkjych (hvwnmpszrv, rpwlcqhfup - muzqnfsmvc) View more
NCT02477423 (CTgov)	Not Applicable	Enterocolitis, Necrotizing \| Obstetric Labor, Premature	27	Gentamicins+Ampicillin (Randomized & Blinded - Receiving Antibiotics)	etwjpuapsj(rqwgmkvtec) = cytlcsqryo iczhlcmzuq (abrfdderlw, 5.3) View more	-	03 Sep 2020
				Placebo (Randomized & Blinded - Receiving Placebo)	etwjpuapsj(rqwgmkvtec) = ocyedaxoat iczhlcmzuq (abrfdderlw, 6.9) View more
NCT02384200 (CTgov)	Phase 4	Kidney Calculi \| Urinary Tract Infections	86	nitrofurantoin monohydrate+gentamicin+ceftriaxone+ampicillin+Vancomycin (Antibiotic)	tfxehzckaw = bytmgelofj gdxbqrgnbl (lirmpnhnbr, gwjgeqghsk - pdapzopapg) View more	-	22 Aug 2019
				gentamicin+ceftriaxone+ampicillin+Vancomycin (No Preoperative Oral Antibiotics)	tfxehzckaw = exjamkbmyi gdxbqrgnbl (lirmpnhnbr, ixcepolnqy - pmyplujyzr) View more
NCT01994993 (SCAMP, CTgov)	Phase 2/3	Complicated intra-abdominal infection	260	gentamicin+metronidazole+Ampicillin (Group 1)	watybxqyis = ldogcguifm tbscfyrzcm (sfwfaqrtlp, yxostwrxsj - qgfmdiodnn) View more	-	27 Feb 2018
				gentamicin+ampicillin+clindamycin (Group 2)	watybxqyis = vkdbwbgnzg tbscfyrzcm (sfwfaqrtlp, uzikykomcc - mylfltiggg) View more
NCT00879190 (CTgov)	Phase 2/3	Chorioamnionitis	92	Unasyn (Unasyn (Ampicillin/Sulbactam))	xogkfgvnen = gzqtdrazhx ihbkecfpcw (aeziqiznpc, eblyhmwsht - oossggztin) View more	-	15 Mar 2017
				gentamicin+Ampicillin (Ampicillin/Gentamicin)	xogkfgvnen = dvyifbxpao ihbkecfpcw (aeziqiznpc, udatkkooot - azylkbrxpb) View more
IAS2004	Not Applicable	Chorioamnionitis	1,570	Active treatment (metronidazole 250 mg TID/erythromycin 500 mg TID)	yqpxultztc(mtafajzhoe) = rzrqdjodze cucepslvou (xddysvkwzx )	-	01 Jan 2004
				Placebo	yqpxultztc(mtafajzhoe) = qkxtbywryw cucepslvou (xddysvkwzx )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis